Anakinra compared with tocilizumab for new-onset refractory status epilepticus
Treatments studied
Part of Brain & nervous system clinical trials.
This study compares two anti-inflammatory drugs, anakinra and tocilizumab, to see which is better at calming prolonged seizures that don't respond to standard treatments. It is for patients with new-onset refractory status epilepticus (NORSE), a rare condition where seizures continue despite multiple medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 2 years or older.
- Have a sudden, intense episode of seizures that do not stop even after two different rescue medicines.
- Be in your usual state of health before the seizures started, meaning you do not have active epilepsy or another related brain condition.
- Doctors must not find an immediate cause (like a stroke, infection, or severe metabolic problem) within the first 72 hours of the seizures.
- If you join the randomized (treatment assignment) part, the seizures must have started within the past 7 days and your doctor must be already planning or considering one of the study drugs.
- Have no serious active medical illness (such as advanced cancer, kidney or liver failure, or poorly controlled diabetes) and no contraindications to the study medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether ketamine can help stop seizures that haven't responded to standard treatments. It's for people with a serious condition called status epilepticus, where seizures don't stop on their own.
This study tests a medicine called anakinra (usually used for inflammation) to see if it helps improve recovery after a stroke caused by a blocked artery that was successfully opened with a procedure. It aims to reduce brain damage and improve outcomes for patients who still have significant symptoms after treatment.
This Phase 2/3 trial studies whether anakinra can improve ongoing (post-acute) COVID-19 symptoms lasting for more than two months. It mainly looks for better safety and symptom improvement in people with specific inflammation and lung-related findings.
This study compares two treatments—anakinra and IVIG—for children with Kawasaki disease who still have fever after their first standard IVIG treatment. It aims to find which option works better and is safer for “IVIG non-responders” who may be at risk for heart complications.
This study tests whether a drug called anakinra, given as a shot, can help treat moderate asthma attacks right when they happen, reducing the need for other rescue treatments. It may help people whose asthma is not well controlled and who have needed steroids in the past year.
This study compares two ways to stop non-convulsive seizures in the ICU. It tests whether fast sedation in intensive care works better than giving higher-dose anti-seizure medicine through a vein.
Hear when a new New Onset Refractory Status Epilepticus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.